{ "model": "qwen/qwen3.6-35b-a3b", "started_at": "2026-05-27T19:50:11.786Z", "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n last 90 days totaling ≥ $500K\n • +3 pts if CEO is among the buyers\n • +3 pts if CFO is among the buyers\n • +2 pts if total purchases > $5M\n • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n • +3 pts if it's in the manager's top-3 positions\n • 2 pts for politician STOCK Act recent buy\n • +1 pt if multiple unrelated members bought within 30 days\n • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n and flow_strength ∈ {moderate, strong}\n • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n • 1 pt: large OI building at a defended price level\n • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n • 8 pts: pending product launch / FDA / contract milestone in horizon\n • 5 pts: recent guidance raise (last 90 days)\n • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n to this name in $)\n Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n earnings)\n • 4 pts: EV/EBITDA ≥ 30% below sector median\n • 4 pts: FCF yield ≥ 7% with stable FCF\n • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n • 5 pts: ROIC ≥ 15% (or trending there)\n • 5 pts: gross margin expanding ≥ 3pp YoY\n • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n • 3 pts: above both 50DMA and 200DMA\n • 4 pts: 12-1 month price return positive AND beating sector\n • 2 pts: RSI 14 in 40-65 zone\n • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n \"core\" — market_cap > $5B. Standard methodology sizing.\n \"asymmetric\" — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n bets lose money or go to zero; the few that work pay\n for the rest. Position sizing is far more conservative\n to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n CORE risk_class:\n ≥ 80 Publish, confidence 5, position size cap 4-5%\n 70-79 Publish, confidence 4, position size cap 2.5-3.0%\n 60-69 Publish, confidence 3, position size cap 1.5-2.0%\n 50-59 Skip unless catalyst <30d + insider cluster\n < 50 Skip\n\n ASYMMETRIC risk_class — strict sizing:\n ≥ 80 Publish, confidence 5, position size cap 1.5%\n 70-79 Publish, confidence 4, position size cap 1.0%\n 60-69 Publish, confidence 3, position size cap 0.5%\n < 60 Skip (no exception; small caps need a clear catalyst)\n Structure must be long_stock (options structures are wrong shape for\n moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n • Going-concern audit qualification\n • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n • Customer concentration > 30%\n • Convertible/warrant overhang creating dilution > 10% of float\n • Accounting irregularities (restatements, auditor changes)\n • Avg daily volume < $5M (liquidity gate)\n • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n verdict='promising' → long_stock | csp (for asymmetric long)\n verdict='range_bound_or_income' → cc | strangle | csp on pullback\n (DON'T default to long_stock — Scout\n already said this isn't an asymmetric\n long. Look at IV elevated → strangle;\n stock at 52w high, fundamentals healthy\n → cc against implicit long; pullback\n thesis with cash → csp)\n verdict='bearish_setup' → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n long_stock — multi-quarter asymmetric thesis, IV not elevated, want\n full upside participation\n csp — bullish, want to own at strike, IV elevated, ann yield ≥15%\n cc — range-bound or mildly bullish, IV elevated, on top of long\n stock leg, if-called return ≥15% ann\n strangle — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n put. Need: comfortable owning at put_strike, no parabolic\n upside expectation. Ann yield ≥12%. Compute and emit\n breakeven_high (call_strike + total_premium) and\n breakeven_low (put_strike - total_premium).\n naked_put — same setup as CSP but using margin. ~2x yield, margin call\n risk. Only for margin-equipped accounts. Note explicitly.\n naked_call — bearish setup with elevated IV. UNCAPPED loss if rally.\n Confidence ceiling 4 (Compliance enforces). Requires\n explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n {\n \"skip\": true,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n \"skip\": false,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"draft\": {\n \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n \"symbol\": \"TICKER\",\n \"company\": \"Full name\",\n \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n \"risk_class\": \"core\" | \"asymmetric\",\n \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n \"thesis_short\": \"1 sentence — why this trade exists.\",\n \"thesis_long\": [\n \"Opening paragraph framing the setup.\",\n \"## Catalyst\",\n \"Detailed catalyst narrative.\",\n \"## Why the market is mispricing this\",\n \"Edge explanation, citing dossier facts.\",\n \"## Numbers\",\n \"- Bullet 1 with concrete numbers from the dossier\",\n \"- Bullet 2\",\n \"## Risk\",\n \"Honest description of what could go wrong.\"\n ],\n \"structure\": {\n \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n \"long_stock\": { \"entry_zone_low\": , \"entry_zone_high\": , \"shares_per_unit\": 100 },\n \"csp\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"if_assigned_basis\": },\n \"cc\": { \"underlying_basis\": , \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"if_called_return_pct\": },\n \"strangle\": { \"call_strike\": , \"put_strike\": , \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": , \"put_premium_target\": , \"total_premium_target\": , \"breakeven_high\": , \"breakeven_low\": , \"annualized_yield_pct\": , \"max_loss_note\": \"...\" },\n \"naked_put\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss_per_contract\": , \"margin_estimate_per_contract\": , \"warning\": \"...\" },\n \"naked_call\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n },\n \"entry\": {\n \"price_at_idea\": ,\n \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n },\n \"exit\": {\n \"target_price\": ,\n \"time_horizon_months\": ,\n \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n },\n \"risk\": {\n \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n },\n \"sources\": [\n { \"label\": \"...\", \"url\": \"...\" }\n ],\n \"confidence\": <1-5, conservative>,\n \"analyst\": \"research-desk\",\n \"scout_model\": \"minimax/minimax-m2.7\",\n \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n \"devils_advocate_verdict\": null\n }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.", "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n \"symbol\": \"OTLK\",\n \"company\": \"Outlook Therapeutics, Inc.\",\n \"investigation_summary\": \"OTLK has triggered on an insider cluster (4 directors buying open-market shares over May 26-27 at $0.40-$0.44, totaling ~$243K) coinciding with a major positive catalyst — the FDA granted its Formal Dispute Resolution appeal on May 26, concluding substantial evidence of effectiveness exists for LYTENAVA (bevacizumab-vikg) in neovascular AMD and directing staff to finalize labeling. The company plans a Class 1 BLA resubmission by June 2026 with an accelerated review timeline. However, the stock has already surged ~170% from its March low ($0.198) to $0.536 on this news, creating significant timing risk for new entry. Underlying fundamentals remain extremely distressed — pre-revenue, -$633M accumulated deficit, going-concern qualified financials, only $7.7M cash against near-term debt maturities of ~$27M, and massive ongoing dilution (shares outstanding doubled in 6 months to 105M). No 13F or politician trade data available. Options IV is extremely elevated (~160-215%), making premium collection strategies attractive for those who want exposure without directional risk at these levels.\",\n \"verdict\": \"range_bound_or_income\",\n \"confidence_in_data\": 4,\n \"structure_hints\": [\n \"csp\",\n \"strangle\"\n ],\n \"business_snapshot\": \"Outlook Therapeutics is a clinical-stage biopharma that has developed LYTENAVA (bevacizumab gamma) — the first and only FDA-approved ophthalmic formulation of bevacizumab, currently approved in Germany and UK for wet AMD. The company launched commercially in June 2025 but generates minimal revenue ($127K last reported quarter). Its entire investment thesis rests on FDA approval for the US market. The product is a reformulated anti-VEGF monoclonal antibody competing against Lucentis (ranibizumab) and Eylea — a $8.5B US retina market where off-label repackaged bevacizumab currently holds 34-66% share depending on geography. OTLK's clinical program had repeated regulatory setbacks: two complete response letters, a failed non-inferiority study (NORSE EIGHT missed week 8 endpoint), and multiple BLA resubmissions. The May 26 FDR victory is the first clear positive signal from FDA in over a year, establishing that substantial evidence of efficacy has been demonstrated. Underlying business economics are challenged: 17 employees, severe working capital deficit, ~$27M in near-term debt maturities (Avondale convertible note + Atlas unsecured note), and no path to profitability without US approval. The company is heavily dependent on external financing.\",\n \"scoring_inputs\": {\n \"smart_money\": {\n \"insider_open_market_purchases_90d\": [\n {\n \"insider\": \"Faisal Ghiath Sukhtian\",\n \"role\": \"Director / 10% Owner\",\n \"amount_usd\": 50000,\n \"date\": \"2026-05-27\",\n \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000004/xslF345X06/primary_doc.xml\"\n },\n {\n \"insider\": \"Yezan Munther Haddadin\",\n \"role\": \"Director\",\n \"amount_usd\": 14960,\n \"date\": \"2026-05-26\",\n \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000003/xslF345X06/primary_doc.xml\"\n },\n {\n \"insider\": \"Randy H. Thurman\",\n \"role\": \"Director\",\n \"amount_usd\": 2145,\n \"date\": \"2026-05-26\",\n \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000002/xslF345X06/primary_doc.xml\"\n },\n {\n \"insider\": \"Kurt J. Hilzinger\",\n \"role\": \"Director (likely Chairman)\",\n \"amount_usd\": 176520,\n \"date\": \"2026-05-26\",\n \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000001/xslF345X06/primary_doc.xml\"\n }\n ],\n \"insider_open_market_total_usd_90d\": 243625,\n \"distinct_insider_buyers_90d\": 4,\n \"ceo_buy_present\": false,\n \"cfo_buy_present\": false,\n \"material_insider_selling_90d_usd\": 0,\n \"notable_13f_holders\": [\n \"pending — v2\"\n ],\n \"politician_recent_buys\": [\n \"pending — v2\"\n ]\n },\n \"catalyst\": {\n \"next_earnings_date\": \"2026-08-13\",\n \"recent_eps_surprise_pattern\": \"Consistent negative surprises: -12.8%, -17.2%, -26.9%, -43.3% over last 4 quarters; all misses worse than prior quarter.\",\n \"guidance_raise_in_last_90d\": false,\n \"named_catalysts\": [\n {\n \"type\": \"regulatory\",\n \"description\": \"FDA granted appeal from Formal Dispute Resolution, concluding substantial evidence of effectiveness established for LYTENAVA in nAMD; directed Division of Ophthalmology to finalize labeling. BLA resubmission expected June 2026 as Class 1 submission.\",\n \"date_or_window\": \"May 26, 2026 / Class 1 review = ~6-month PDUFA window\",\n \"source_urls\": [\n \"https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/tm2615583d1_8k.htm\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"product\",\n \"description\": \"LYTENAVA launched commercially in Germany and UK (June 2025); generating minimal early revenue ($127K Q2 FY26). Swiss distribution agreement with Mediconsult AG.\",\n \"date_or_window\": \"Ongoing\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/outlook-therapeutics-reports-second-quarter-200500436.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"regulatory\",\n \"description\": \"NORSE EIGHT trial failed pre-specified non-inferiority endpoint at week 8 (Nov 2024). However, FDA's May 2026 FDR decision superseded this concern by accepting prior NORSE TWO as sufficient evidence.\",\n \"date_or_window\": \"November 2024 (mitigated May 2026)\",\n \"source_urls\": [\n \"https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm\"\n ],\n \"directional_bias\": \"ambiguous\"\n }\n ]\n },\n \"mispricing\": {\n \"forward_pe\": -2.01,\n \"sector_median_forward_pe\": null,\n \"ev_to_ebitda\": -1.12,\n \"sector_median_ev_to_ebitda\": null,\n \"fcf_yield_pct\": 0,\n \"narrative\": \"As a pre-revenue biopharma with no path to profitability in visible horizon, traditional valuation multiples are irrelevant. Market cap of ~$65M reflects discounted probability of FDA approval and US commercial launch. With FDR appeal won, the market repriced significantly upward over 2 days (+33% on news day alone), compressing remaining upside vs. prior CRL levels.\",\n \"sotp_gap_pct\": null\n },\n \"quality\": {\n \"roic_pct\": null,\n \"gross_margin_trend_pp_yoy\": null,\n \"net_debt_to_ebitda\": null,\n \"balance_sheet_grade\": \"D\"\n },\n \"technical\": {\n \"above_50dma\": true,\n \"above_200dma\": false,\n \"rsi_14\": 79.1,\n \"macd_recent_bullish_cross\": true,\n \"12_1_momentum_vs_sector_pct\": null\n }\n },\n \"price_context\": {\n \"last_close\": 0.536,\n \"ytd_return_pct\": -47.45,\n \"from_52w_high_pct\": -84\n },\n \"filings_reviewed\": [\n {\n \"form\": \"10-K\",\n \"filed\": \"2025-12-19\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm\",\n \"key_takeaways\": [\n \"FY2025 ended Sep 30, 2025: accumulated deficit $605M; cash $8.1M vs $27.2M prior year; multiple financing rounds in FY25 including ATM offerings and convertible notes; going concern disclosed; shares outstanding ~54M at fiscal year end but grew to 120M by March 2026\",\n \"NORSE EIGHT missed pre-specified non-inferiority endpoint at week 8 (Nov 2024); company resubmitted BLA Feb 2025; second CRL received Aug 27, 2025 citing single deficiency: lack of substantial evidence of effectiveness\",\n \"Product launched in Germany and UK June 2025 as LYTENAVA; EU market estimated $3.6B total anti-VEGF; US market $8.5B; off-label bevacizumab currently holds ~34% of US market\"\n ]\n },\n {\n \"form\": \"10-Q\",\n \"filed\": \"2026-05-15\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1649989/000110465926062632/otlk-20260331x10q.htm\",\n \"key_takeaways\": [\n \"Q2 FY26 (Mar 31, 2026): Revenue $127K; net loss ($4.5M); working capital deficit ($18M); cash $7.7M vs liabilities due in near-term of ~$27M (Avondale convertible note + Atlas unsecured note)\",\n \"Shares outstanding grew to 104.6M by Mar 31, 2026 from 53.9M at Sep 30, 2025 — nearly doubled in 6 months via offerings and conversions; warrant liability $722K vs $4.8M prior year\",\n \"Major Trigger Event on Dec 31, 2025: company failed $3M quarterly debt reduction obligation under Avondale note, triggering automatic 10% balance increase and conversion price adjustment (floor $0.404). Management states existing cash insufficient to fund operations for one year.\"\n ]\n },\n {\n \"form\": \"8-K\",\n \"filed\": \"2026-05-26\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/tm2615583d1_8k.htm\",\n \"key_takeaways\": [\n \"FDA granted appeal from Formal Dispute Resolution (FDR) — concludes substantial evidence of effectiveness established for LYTENAVA in nAMD. Directs Division of Ophthalmology to finalize labeling.\",\n \"Company expects BLA resubmission June 2026 as Class 1 submission (6-month review). This is the most significant positive regulatory event in company's history and directly addresses the root cause of prior CRL.\"\n ]\n }\n ],\n \"options_context\": {\n \"expiries_examined\": [\n \"2026-08-21\"\n ],\n \"iv_summary\": \"ATM IV at Aug 21 expiry ~160-215% depending on strike — extremely elevated, consistent with binary-event biotech. The stock's post-May 26 surge to $0.54 from sub-$0.40 levels has created a situation where the market is pricing in significant FDA approval probability.\",\n \"notable_skew_or_flow\": \"Put/call ratio 0.29 (bullish lean but not overwhelming). Net dollar bias -$7,886 (slightly bearish flow at these elevated prices — possibly hedging from earlier calls or profit-taking positioning). Top OI on $0.50 calls (1,257) vs $0.50 puts (143). No whale blocks detected. High IV environment makes selling premium attractive but binary event risk is extreme.\"\n },\n \"competitive_landscape\": \"OTLK competes in the ~$8.5B US anti-VEGF retina market with LYTENAVA (bevacizumab-vikg) against: Roche/Novartis' Lucentis ($6.2B global sales at peak), Regeneron's Eylea/Brolucizumab franchise, and off-label repackaged bevacizumab (currently ~34% of US market). The value proposition is that LYTENAVA would be the ONLY FDA-approved ophthalmic bevacizumab — eliminating sterility/variability risks of compounded product while potentially being priced lower than branded competitors. In EU/UK it has first-mover advantage as sole approved formulation.\",\n \"key_risks\": [\n \"Binary regulatory risk: FDA approval not yet received; Class 1 resubmission still required, expected June 2026\",\n \"Extreme balance sheet distress: Going concern qualified, only $7.7M cash vs ~$27M near-term debt maturities, current ratio 0.54 — insolvency risk without additional capital raises\",\n \"Severe dilution: Shares outstanding doubled in 6 months; large warrant overhang (56.8M equivalent shares) will continue to dilute\",\n \"NORSE EIGHT clinical failure: Week 8 non-inferiority endpoint missed; FDA's FDR reversal is the only path forward but creates uncertainty on final labeling/conditions\",\n \"Off-label competition remains entrenched even if approved — payer coverage, physician prescribing habits, and institutional formulary decisions all favor established brands\",\n \"No CEO/CFO open-market purchases in recent period (only directors); CEO Lawrence Kenyon has not filed personal open-market buys recently\",\n \"Securities class action lawsuit pending; company and certain officers named as defendants\"\n ],\n \"what_the_market_might_be_missing\": \"The FDR appeal win on May 26 is unambiguous — FDA concluded 'substantial evidence of effectiveness established' for LYTENAVA in nAMD. This resolves the core deficiency cited in all prior CRLs (lack of substantial evidence). The market appears to be treating this as binary event pricing rather than near-certainty approval. However, timing risk and post-approval commercial execution remain major unknowns. On the flip side: the stock already ran from ~$0.40 pre-May 26 announcement to $0.54 today (+34%), leaving limited upside for a trade that requires FDA final label agreement, BLA resubmission, review, and approval — likely not before late 2026 at earliest.\",\n \"anti_signals_present\": [\n \"going_concern\",\n \"dilution\",\n \"low_liquidity\",\n \"litigation\"\n ],\n \"sources\": [\n {\n \"label\": \"Form 4 - Sukhtian (May 27)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000004/xslF345X06/primary_doc.xml\"\n },\n {\n \"label\": \"Form 4 - Hilzinger (May 26)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1649989/000164998926000001/xslF345X06/primary_doc.xml\"\n },\n {\n \"label\": \"FDA Appeal Win 8-K (May 26, 2026)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1649989/000110465926065992/tm2615583d1_8k.htm\"\n },\n {\n \"label\": \"FY2025 10-K\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1649989/000110465925123264/otlk-20250930x10k.htm\"\n },\n {\n \"label\": \"Q2 FY26 10-Q (Mar 31, 2026)\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1649989/000110465926062632/otlk-20260331x10q.htm\"\n }\n ],\n \"unfetched_signals\": [\n \"13f_deltas\",\n \"politician_trades\",\n \"sentiment_score\"\n ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude ... reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.", "completions": [ { "ts": "2026-05-27T19:50:49.394Z", "raw_content": "The dossier is for OTLK (Outlook Therapeutics, Inc.).\nLet's check the risk class: market_cap is not explicitly given, but price is $0.536, shares outstanding ~105M. Market cap ~$56M. This is ≤ $5B, so it's \"asymmetric\".\nWait, the prompt says: \"asymmetric — market_cap ≤ $5B (small-cap moonshot).\"\nActually, let's look at the anti-signal gates:\n\"anti_signals_present\": [\n \"going_concern\",\n \"dilution\",\n \"low_liquidity\",\n \"litigation\"\n]\nThe prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nAlso, \"Going-concern audit qualification\" is a gate.\n\"Pending material litigation (DOE/SEC enforcement, class action with merit)\" is a gate.\n\"Customer concentration > 30%\" - not mentioned.\n\"Convertible/warrant overhang creating dilution > 10% of float\" - warrant overhang is 56.8M equivalent shares (54% of float). This is a gate.\n\"Accounting irregularities\" - not mentioned.\n\"Avg daily volume < $5M\" - low liquidity gate.\n\"Pump-and-dump signals\" - not mentioned.\n\nGiven the anti-signals, I should skip.\nBut let's score it anyway to be sure, and follow the prompt's structure for skipping.\nWait, the prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will skip and explain the anti-signals.\n\nLet's score it quickly:\nA. Smart Money: 4 distinct insiders bought, total $243K. Not ≥ $500K. No CEO/CFO. Total < $5M. No 13F. 0 pts.\nB. Options Flow: IV elevated (160-215%), but no whale blocks. Put/call ratio 0.29. Net dollar bias slightly bearish. 0 pts.\nC. Catalyst: FDA appeal win is strong, but not earnings within 90d with positive surprises. It's a regulatory catalyst. 8 pts for pending product launch/FDA? Actually, it's a Class 1 BLA resubmission. Let's give 8 pts.\nD. Mispricing: Pre-revenue, negative multiples. 0 pts.\nE. Quality: Going concern, D balance sheet. 0 pts.\nF. Technical: RSI 79.1 (overbought), above 50DMA but not 200DMA. 1 pt.\nTotal score: ~17.\nAsymmetric risk class: < 60 Skip.\nAlso, anti-signal gates trigger skip.\nThe prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will skip.\n\nReason: The dossier triggers multiple anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) that override any regulatory catalyst. Additionally, the stock has already surged 170% from its March low, leaving poor risk/reward for an asymmetric small-cap with a distressed balance sheet ($7.7M cash vs $27M near-term debt).\n\nI will output the skip JSON.\nCheck structure:\n{\n \"skip\": true,\n \"score\": ,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"...\"\n}\n\nScore breakdown:\nsmart_money: 0\noptions_flow: 0\ncatalyst: 8\nmispricing: 0\nquality: 0\ntechnical: 1\nTotal: 9\n\nWait, let's recalculate catalyst carefully.\n\"8 pts: pending product launch / FDA / contract milestone in horizon\" -> The BLA resubmission is in June 2026. So 8 pts.\nTotal: 9.\nI'll put 9.\n\nReason: \"Anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) trigger an automatic skip. Furthermore, the stock has already run up 170% from its March low, and the balance sheet is critically distressed ($7.7M cash vs ~$27M near-term debt), making any structure highly speculative with poor risk/reward.\"\n\nCheck prompt requirements for skip:\n\"IF YOU SKIP — output exactly:\n {\n \"skip\": true,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n }\"\n\nAll good. I will generate exactly this.\nOne minor thing: The prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\" I will articulate that they do apply.\nReady.✅\nOutput matches requirement.\nProceeds. \nLet's double check the score calculation just in case.\nA: 0\nB: 0\nC: 8\nD: 0\nE: 0\nF: 1\nTotal: 9.\nFits asymmetric <60 skip rule.\nAnti-signal gates also trigger skip.\nAll consistent.\nOutput matches exactly. \nProceed. \n[Output Generation] -> JSON only. \nNo extra text.\nDone. \nSelf-Correction/Verification during thought:\nWait, the prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will mention that in the reason.\nThe reason should be concise.\n\"Anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) trigger an automatic skip. Furthermore, the stock has already surged 170% from its March low, and the balance sheet is critically distressed ($7.7M cash vs ~$27M near-term debt), making any structure highly speculative with poor risk/reward.\"\nMatches perfectly.\nProceeds. \nOutput matches requested format.\nDone. \n[Output Generation]\n```json\n{\n \"skip\": true,\n \"score\": 9,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 8,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 1\n },\n \"reason\": \"Anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) trigger an automatic skip. Furthermore, the stock has already surged 170% from its March low, and the balance sheet is critically distressed ($7.7M cash vs ~$27M near-term debt), making any structure highly speculative with poor risk/reward.\"\n}\n```\nWait, the prompt says \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will output raw JSON without markdown fences.\nCheck formatting carefully.\nAll good.\nProceeds. \n(Self-Correction/Refinement during generation prep)\nI will ensure no markdown code blocks are used, as per \"No surrounding prose, no markdown fences.\"\nReady. \nOutput matches exactly. \nProceeds. \n[Final Check of the Prompt]\n\"IF YOU SKIP — output exactly: ...\"\n\"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will strictly follow this.\nDone. \nOutput Generation. \n[Done] \n`{ \"skip\": true, \"score\": 9, \"score_breakdown\": { \"smart_money\": 0, \"options_flow\": 0, \"catalyst\": 8, \"mispricing\": 0, \"quality\": 0, \"technical\": 1 }, \"reason\": \"Anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) trigger an automatic skip. Furthermore, the stock has already surged 170% from its March low, and the balance sheet is critically distressed ($7.7M cash vs ~$27M near-term debt), making any structure highly speculative with poor risk/reward.\" }`\nMatches.\nProceeds. \n[Output Generation] (raw string)\n{\n \"skip\": true,\n \"score\": 9,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 8,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 1\n },\n \"reason\": \"Anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) trigger an automatic skip. Furthermore, the stock has already surged 170% from its March low, and the balance sheet is critically distressed ($7.7M cash vs ~$27M near-term debt), making any structure highly speculative with poor risk/reward.\"\n}\nDone. \n(Self-Correction/Note during thought: I should verify the catalyst score. The prompt says \"8 pts: pending product launch / FDA / contract milestone in horizon\". The dossier says \"BLA resubmission expected June 2026 as Class 1 submission\". That's a horizon catalyst. So 8 is fair. Even if I adjust to 10, score is still <60. Skip is robust.)\nProceeds. \nOutput matches. \n[Final Output Generation] -> *Proceeds*\n\n\n{\n \"skip\": true,\n \"score\": 9,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 8,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 1\n },\n \"reason\": \"Anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) trigger an automatic skip. Furthermore, the stock has already surged 170% from its March low, and the balance sheet is critically distressed ($7.7M cash vs ~$27M near-term debt), making any structure highly speculative with poor risk/reward.\"\n}", "cleaned_content": "{\n \"skip\": true,\n \"score\": 9,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 8,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 1\n },\n \"reason\": \"Anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) trigger an automatic skip. Furthermore, the stock has already surged 170% from its March low, and the balance sheet is critically distressed ($7.7M cash vs ~$27M near-term debt), making any structure highly speculative with poor risk/reward.\"\n}", "tool_calls": null, "finish_reason": "stop" } ], "tool_results": [], "final_message": "{\n \"skip\": true,\n \"score\": 9,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 0,\n \"catalyst\": 8,\n \"mispricing\": 0,\n \"quality\": 0,\n \"technical\": 1\n },\n \"reason\": \"Anti-signal gates (going-concern qualification, >10% warrant overhang, pending litigation, and low liquidity) trigger an automatic skip. Furthermore, the stock has already surged 170% from its March low, and the balance sheet is critically distressed ($7.7M cash vs ~$27M near-term debt), making any structure highly speculative with poor risk/reward.\"\n}", "tool_calls_total": 0, "walltime_ms": 37608, "stop_reason": "stop", "completed_at": "2026-05-27T19:50:49.394Z" }